MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

About this update from Moonlake Immunotherapeutics

MoonLake Immunot herapeutics achieves landmark milestone with positive Phase 2 results for Nanobody ® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS HiSCR50 met with 38 ppt delta vs placebo (p

View stock analysis, news, and events for Moonlake Immunotherapeutics